![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
EDP-514, a Novel Pangenotypic Class II Hepatitis B Virus Core Inhibitor: Final Resultsof a Phase 1 Study in Healthy Adult Subjects
|
|
|
EASL 2020 Aug 27-29 virtual
Reported by Jules Levin
Kajal Larson1, Alaa Ahmad1, Eoin Coakley1, Ty McClure1, Jingwen Chai1, Daniel Dickerson2, and Nathalie Adda1
1Enanta Pharmaceuticals, Inc., Watertown, Massachusetts, USA; 2PRA Health Sciences -Lenexa, Lenexa, Kansas, USA
![0918201](../images/091820/091820-1/0918201.gif)
![0918202](../images/091820/091820-1/0918202.gif)
![0918203](../images/091820/091820-1/0918203.gif)
![0918204](../images/091820/091820-1/0918204.gif)
![0918205](../images/091820/091820-1/0918205.gif)
![0918206](../images/091820/091820-1/0918206.gif)
![0918207](../images/091820/091820-1/0918207.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|